

## **PRIOR AUTHORIZATION REQUEST**

Nucleoside Reverse Transcriptase Inhibitors, non-nukes (NNRTIs) Medications

	Name	Prescriber:	Name	
	Address:		Address	
	City, State, Zip		City, State, Zip	
	D.O.B		Phone	
	Member ID:		Fax	
			NPI	

## **Medication Requested:**

Edurant® (rilprivine) Intelence® (etravirine) Pifeltro® (doravirine) Rescriptor® (delaviridine)

Viramune/Viramune XR® (nevirapine)

Qty Requested: \_\_\_\_\_

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

## SECTION A Please answer the following questions

- 1. Yes No Has the member been diagnosed as having a positive test for an HIV-1 infection?
- 2. □ Yes No Has the patient tried and failed Sustiva®> or shows resistance to Sustiva®? (defined as lab tests showing plasma HIV RNA VL >200 copies/mL after 2 months of therapy)?

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B Physician Signature

PHYSICIAN SIGNATURE

DATE

SECTION C References:

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available

at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Section accessed [11/2019]

## FAX COMPLETED FORM TO: 877-251-5896

**Disclaimer:** An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**Confidentiality:** The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 800-753-2851